Lymphopenia at diagnosis predicts survival of patients with immunodeficiency-associated lymphoproliferative disorders
The number of patients who are administered immunosuppressive agents has been increasing. Accordingly, more patients face higher risks for developing immunodeficiency-associated lymphoproliferative disorders (LPD). Although immunodeficiency-associated LPD are distinct from other lymphoid neoplasms i...
Saved in:
| Published in | Annals of hematology Vol. 99; no. 7; pp. 1565 - 1573 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Berlin/Heidelberg
Springer Berlin Heidelberg
01.07.2020
Springer Nature B.V |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0939-5555 1432-0584 1432-0584 |
| DOI | 10.1007/s00277-020-04084-5 |
Cover
| Abstract | The number of patients who are administered immunosuppressive agents has been increasing. Accordingly, more patients face higher risks for developing immunodeficiency-associated lymphoproliferative disorders (LPD). Although immunodeficiency-associated LPD are distinct from other lymphoid neoplasms in terms of their immunocompromised backgrounds, little is known about the impact of lymphopenia at diagnosis on survival in patients with these LPD. Seventy-one immunodeficiency-associated LPD in Kyoto University Hospital (post-transplant LPD (PTLD),
n
= 26; other iatrogenic immunodeficiency-associated LPD,
n
= 45) were reviewed and analyzed. The median age at diagnosis was 63 years (range, 3–83). Diffuse large B cell lymphoma was the most common subtype (
n
= 33), followed by Hodgkin lymphoma (
n
= 12), B cell monomorphic LPD not specified (
n
= 11), and polymorphic LPD or early-phase diseases (
n
= 15). The median follow-up period for survivors was 2.5 years and overall survival (OS) and progression-free survival (PFS) at 2.5 years were 75% and 67%, respectively. Multivariate analysis showed that lymphopenia (≤ 800/μL) at diagnosis predicted inferior OS (HR, 3.72;
P
= 0.043) and PFS (HR, 3.82;
P
= 0.012). Serum albumin values also strongly affected OS (> 3.18 g/dL vs. ≤ 3.18 g/dL; HR, 0.21;
P
= 0.010) and PFS (HR, 0.26;
P
= 0.013). Lymphopenia at diagnosis is suggested to predict inferior OS and PFS in patients with immunodeficiency-associated LPDs. Immunocompromised status might affect disease progression in these distinct lymphoid neoplasms growing under immunocompromised backgrounds. |
|---|---|
| AbstractList | The number of patients who are administered immunosuppressive agents has been increasing. Accordingly, more patients face higher risks for developing immunodeficiency-associated lymphoproliferative disorders (LPD). Although immunodeficiency-associated LPD are distinct from other lymphoid neoplasms in terms of their immunocompromised backgrounds, little is known about the impact of lymphopenia at diagnosis on survival in patients with these LPD. Seventy-one immunodeficiency-associated LPD in Kyoto University Hospital (post-transplant LPD (PTLD), n = 26; other iatrogenic immunodeficiency-associated LPD, n = 45) were reviewed and analyzed. The median age at diagnosis was 63 years (range, 3-83). Diffuse large B cell lymphoma was the most common subtype (n = 33), followed by Hodgkin lymphoma (n = 12), B cell monomorphic LPD not specified (n = 11), and polymorphic LPD or early-phase diseases (n = 15). The median follow-up period for survivors was 2.5 years and overall survival (OS) and progression-free survival (PFS) at 2.5 years were 75% and 67%, respectively. Multivariate analysis showed that lymphopenia (≤ 800/μL) at diagnosis predicted inferior OS (HR, 3.72; P = 0.043) and PFS (HR, 3.82; P = 0.012). Serum albumin values also strongly affected OS (> 3.18 g/dL vs. ≤ 3.18 g/dL; HR, 0.21; P = 0.010) and PFS (HR, 0.26; P = 0.013). Lymphopenia at diagnosis is suggested to predict inferior OS and PFS in patients with immunodeficiency-associated LPDs. Immunocompromised status might affect disease progression in these distinct lymphoid neoplasms growing under immunocompromised backgrounds. The number of patients who are administered immunosuppressive agents has been increasing. Accordingly, more patients face higher risks for developing immunodeficiency-associated lymphoproliferative disorders (LPD). Although immunodeficiency-associated LPD are distinct from other lymphoid neoplasms in terms of their immunocompromised backgrounds, little is known about the impact of lymphopenia at diagnosis on survival in patients with these LPD. Seventy-one immunodeficiency-associated LPD in Kyoto University Hospital (post-transplant LPD (PTLD), n = 26; other iatrogenic immunodeficiency-associated LPD, n = 45) were reviewed and analyzed. The median age at diagnosis was 63 years (range, 3-83). Diffuse large B cell lymphoma was the most common subtype (n = 33), followed by Hodgkin lymphoma (n = 12), B cell monomorphic LPD not specified (n = 11), and polymorphic LPD or early-phase diseases (n = 15). The median follow-up period for survivors was 2.5 years and overall survival (OS) and progression-free survival (PFS) at 2.5 years were 75% and 67%, respectively. Multivariate analysis showed that lymphopenia (≤ 800/μL) at diagnosis predicted inferior OS (HR, 3.72; P = 0.043) and PFS (HR, 3.82; P = 0.012). Serum albumin values also strongly affected OS (> 3.18 g/dL vs. ≤ 3.18 g/dL; HR, 0.21; P = 0.010) and PFS (HR, 0.26; P = 0.013). Lymphopenia at diagnosis is suggested to predict inferior OS and PFS in patients with immunodeficiency-associated LPDs. Immunocompromised status might affect disease progression in these distinct lymphoid neoplasms growing under immunocompromised backgrounds.The number of patients who are administered immunosuppressive agents has been increasing. Accordingly, more patients face higher risks for developing immunodeficiency-associated lymphoproliferative disorders (LPD). Although immunodeficiency-associated LPD are distinct from other lymphoid neoplasms in terms of their immunocompromised backgrounds, little is known about the impact of lymphopenia at diagnosis on survival in patients with these LPD. Seventy-one immunodeficiency-associated LPD in Kyoto University Hospital (post-transplant LPD (PTLD), n = 26; other iatrogenic immunodeficiency-associated LPD, n = 45) were reviewed and analyzed. The median age at diagnosis was 63 years (range, 3-83). Diffuse large B cell lymphoma was the most common subtype (n = 33), followed by Hodgkin lymphoma (n = 12), B cell monomorphic LPD not specified (n = 11), and polymorphic LPD or early-phase diseases (n = 15). The median follow-up period for survivors was 2.5 years and overall survival (OS) and progression-free survival (PFS) at 2.5 years were 75% and 67%, respectively. Multivariate analysis showed that lymphopenia (≤ 800/μL) at diagnosis predicted inferior OS (HR, 3.72; P = 0.043) and PFS (HR, 3.82; P = 0.012). Serum albumin values also strongly affected OS (> 3.18 g/dL vs. ≤ 3.18 g/dL; HR, 0.21; P = 0.010) and PFS (HR, 0.26; P = 0.013). Lymphopenia at diagnosis is suggested to predict inferior OS and PFS in patients with immunodeficiency-associated LPDs. Immunocompromised status might affect disease progression in these distinct lymphoid neoplasms growing under immunocompromised backgrounds. The number of patients who are administered immunosuppressive agents has been increasing. Accordingly, more patients face higher risks for developing immunodeficiency-associated lymphoproliferative disorders (LPD). Although immunodeficiency-associated LPD are distinct from other lymphoid neoplasms in terms of their immunocompromised backgrounds, little is known about the impact of lymphopenia at diagnosis on survival in patients with these LPD. Seventy-one immunodeficiency-associated LPD in Kyoto University Hospital (post-transplant LPD (PTLD), n = 26; other iatrogenic immunodeficiency-associated LPD, n = 45) were reviewed and analyzed. The median age at diagnosis was 63 years (range, 3–83). Diffuse large B cell lymphoma was the most common subtype ( n = 33), followed by Hodgkin lymphoma ( n = 12), B cell monomorphic LPD not specified ( n = 11), and polymorphic LPD or early-phase diseases ( n = 15). The median follow-up period for survivors was 2.5 years and overall survival (OS) and progression-free survival (PFS) at 2.5 years were 75% and 67%, respectively. Multivariate analysis showed that lymphopenia (≤ 800/μL) at diagnosis predicted inferior OS (HR, 3.72; P = 0.043) and PFS (HR, 3.82; P = 0.012). Serum albumin values also strongly affected OS (> 3.18 g/dL vs. ≤ 3.18 g/dL; HR, 0.21; P = 0.010) and PFS (HR, 0.26; P = 0.013). Lymphopenia at diagnosis is suggested to predict inferior OS and PFS in patients with immunodeficiency-associated LPDs. Immunocompromised status might affect disease progression in these distinct lymphoid neoplasms growing under immunocompromised backgrounds. The number of patients who are administered immunosuppressive agents has been increasing. Accordingly, more patients face higher risks for developing immunodeficiency-associated lymphoproliferative disorders (LPD). Although immunodeficiency-associated LPD are distinct from other lymphoid neoplasms in terms of their immunocompromised backgrounds, little is known about the impact of lymphopenia at diagnosis on survival in patients with these LPD. Seventy-one immunodeficiency-associated LPD in Kyoto University Hospital (post-transplant LPD (PTLD), n = 26; other iatrogenic immunodeficiency-associated LPD, n = 45) were reviewed and analyzed. The median age at diagnosis was 63 years (range, 3–83). Diffuse large B cell lymphoma was the most common subtype (n = 33), followed by Hodgkin lymphoma (n = 12), B cell monomorphic LPD not specified (n = 11), and polymorphic LPD or early-phase diseases (n = 15). The median follow-up period for survivors was 2.5 years and overall survival (OS) and progression-free survival (PFS) at 2.5 years were 75% and 67%, respectively. Multivariate analysis showed that lymphopenia (≤ 800/μL) at diagnosis predicted inferior OS (HR, 3.72; P = 0.043) and PFS (HR, 3.82; P = 0.012). Serum albumin values also strongly affected OS (> 3.18 g/dL vs. ≤ 3.18 g/dL; HR, 0.21; P = 0.010) and PFS (HR, 0.26; P = 0.013). Lymphopenia at diagnosis is suggested to predict inferior OS and PFS in patients with immunodeficiency-associated LPDs. Immunocompromised status might affect disease progression in these distinct lymphoid neoplasms growing under immunocompromised backgrounds. |
| Author | Watanabe, Mizuki Kondo, Tadakazu Kanda, Junya Takaori-Kondo, Akifumi Yamashita, Kouhei Hishizawa, Masakatsu Nishikori, Momoko |
| Author_xml | – sequence: 1 givenname: Mizuki surname: Watanabe fullname: Watanabe, Mizuki organization: Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University – sequence: 2 givenname: Junya orcidid: 0000-0002-6704-3633 surname: Kanda fullname: Kanda, Junya email: jkanda16@kuhp.kyoto-u.ac.jp organization: Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University – sequence: 3 givenname: Masakatsu surname: Hishizawa fullname: Hishizawa, Masakatsu organization: Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University – sequence: 4 givenname: Momoko surname: Nishikori fullname: Nishikori, Momoko organization: Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University – sequence: 5 givenname: Tadakazu surname: Kondo fullname: Kondo, Tadakazu organization: Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University – sequence: 6 givenname: Kouhei surname: Yamashita fullname: Yamashita, Kouhei organization: Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University – sequence: 7 givenname: Akifumi surname: Takaori-Kondo fullname: Takaori-Kondo, Akifumi organization: Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32436013$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kUtr3TAQhUVJaW7S_oEuiqGbbtyOXra8LKGPwIVu2rXQlcaJgi25knzL_fdR64RCFtFGMHzncGbOBTkLMSAhbyl8pAD9pwzA-r4FBi0IUKKVL8iOCs5akEqckR0MfGhlfefkIuc7AMqUYK_IOWeCd0D5jqz707zcxgWDN40pjfPmJsTsc7MkdN6W3OQ1Hf3RTE0cm8UUj6EO__hy2_h5XkN0OHpbp_bUmpyj9aaga6bNN8XJj5iq7IjVPMfkMOXX5OVopoxvHv5L8uvrl59X39v9j2_XV5_3rRVKlrZXbDCUj9QK4ZQdrVFG9AYts0CtQ4lI-2E4MOUoKgDEzoxDV7eXTB6g45fkw-Zbc_xeMRc9-2xxmkzAuGbNBEjO5TDwir5_gt7FNYWarlK0p13XKVapdw_UepjR6SX52aSTfjxoBdQG2BRzTjhq60vdPoaSjJ80Bf23O711p2t3-l93WlYpeyJ9dH9WxDdRrnC4wfQ_9jOqe9t6rkM |
| CitedBy_id | crossref_primary_10_1111_bjh_17824 crossref_primary_10_1111_ajt_16547 crossref_primary_10_1016_j_intimp_2021_107565 |
| Cites_doi | 10.1159/000072463 10.18632/oncotarget.9400 10.1093/intimm/dxm057 10.1002/art.22277 10.1007/s12307-018-00219-5 10.1080/10428194.2018.1480767 10.1182/blood-2016-02-698936 10.1046/j.1365-2141.2002.03619.x 10.3109/10428194.2015.1022769 10.1038/nrclinonc.2012.111 10.1182/blood-2014-01-553362 10.1002/ajh.21003 10.1182/blood-2010-04-281873 10.1007/s11899-013-0162-5 10.1111/ajt.12196 10.1186/s40425-019-0549-5 10.1002/hon.859 10.1111/bjh.13621 10.1111/bjh.15263 10.1182/blood.V99.11.3909 10.1016/S1470-2045(11)70300-X 10.1016/j.bbmt.2015.07.035 10.1200/JCO.1996.14.6.1943 10.1182/blood-2015-05-615872 10.1016/j.blre.2003.12.002 10.1016/j.transproceed.2016.03.045 10.1111/ajt.12211 10.1016/j.bbmt.2004.05.008 10.1046/j.1365-2559.1996.d01-425.x 10.1111/j.1349-7006.2010.01517.x 10.1038/modpathol.2009.131 10.1002/art.10933 10.1097/TP.0000000000002269 10.18632/oncotarget.5292 10.1002/ajh.24346 10.4291/wjgp.v6.i4.181 10.1182/blood.V97.5.1165 10.1111/ejh.12904 10.1002/hon.2280 10.1016/S0140-6736(03)12271-4 10.1111/bjh.14633 10.1038/s41375-019-0380-5 |
| ContentType | Journal Article |
| Copyright | Springer-Verlag GmbH Germany, part of Springer Nature 2020 Springer-Verlag GmbH Germany, part of Springer Nature 2020. |
| Copyright_xml | – notice: Springer-Verlag GmbH Germany, part of Springer Nature 2020 – notice: Springer-Verlag GmbH Germany, part of Springer Nature 2020. |
| DBID | AAYXX CITATION NPM 3V. 7RV 7X7 7XB 88E 8AO 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH K9. KB0 M0S M1P NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI 7X8 |
| DOI | 10.1007/s00277-020-04084-5 |
| DatabaseName | CrossRef PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One ProQuest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Health & Medical Collection (Alumni) Medical Database Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition MEDLINE - Academic |
| DatabaseTitle | CrossRef PubMed ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic ProQuest One Academic Middle East (New) |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1432-0584 |
| EndPage | 1573 |
| ExternalDocumentID | 32436013 10_1007_s00277_020_04084_5 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: Takeda Science Foundation funderid: http://dx.doi.org/10.13039/100007449 |
| GroupedDBID | --- -53 -5E -5G -BR -EM -Y2 -~C -~X .86 .GJ .VR 06C 06D 0R~ 0VY 199 1N0 1SB 2.D 203 23M 28- 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 36B 3V. 4.4 406 408 409 40D 40E 53G 5GY 5QI 5RE 5VS 67Z 6NX 78A 7RV 7X7 88E 8AO 8FI 8FJ 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AAJSJ AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAWTL AAYIU AAYQN AAYTO AAYZH ABAKF ABBBX ABBXA ABDZT ABECU ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKCH ABKTR ABLJU ABMNI ABMQK ABNWP ABPLI ABQBU ABQSL ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABUWZ ABWNU ABXPI ACAOD ACBXY ACGFS ACHSB ACHVE ACHXU ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACUDM ACULB ACZOJ ADBBV ADHHG ADHIR ADIMF ADINQ ADJJI ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFIE AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFEXP AFFNX AFJLC AFKRA AFLOW AFQWF AFWTZ AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BBWZM BDATZ BENPR BGNMA BKEYQ BPHCQ BSONS BVXVI C6C CAG CCPQU COF CS3 CSCUP DDRTE DL5 DNIVK DPUIP EBD EBLON EBS EIOEI EJD EMB EMOBN EN4 ESBYG EX3 F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GRRUI GXS H13 HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IHE IJ- IKXTQ IMOTQ ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KOW KPH LAS LLZTM M1P M4Y MA- N2Q N9A NAPCQ NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM OVD P19 P2P P9S PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R4E R89 R9I RHV RIG RNI RNS ROL RPX RRX RSV RZK S16 S1Z S26 S27 S28 S37 S3B SAP SCLPG SDE SDH SDM SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TEORI TSG TSK TSV TT1 TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 WOW YLTOR Z45 Z7U Z82 Z83 Z87 Z8O Z8V Z8W Z91 ZMTXR ZOVNA ZXP ~EX ~KM AAPKM AAYXX ABBRH ABDBE ABEEZ ABFSG ACSTC ADHKG AEZWR AFDZB AFGXO AFHIU AFOHR AGQPQ AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT PJZUB PPXIY PUEGO NPM 7XB 8FK K9. PKEHL PQEST PQUKI 7X8 |
| ID | FETCH-LOGICAL-c485t-7829a13f1c44d8cfca8a47aec2c01cde5ee1799b28d1e800ee6af96058525b063 |
| IEDL.DBID | U2A |
| ISSN | 0939-5555 1432-0584 |
| IngestDate | Thu Oct 02 07:38:29 EDT 2025 Tue Oct 07 05:35:11 EDT 2025 Mon Jul 21 06:06:40 EDT 2025 Thu Apr 24 23:05:28 EDT 2025 Wed Oct 01 04:03:57 EDT 2025 Fri Feb 21 02:35:31 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 7 |
| Keywords | Immune-suppressive patients PTLD Immunodeficiency-associated lymphoproliferative disorders Lymphopenia |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c485t-7829a13f1c44d8cfca8a47aec2c01cde5ee1799b28d1e800ee6af96058525b063 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-6704-3633 |
| OpenAccessLink | http://hdl.handle.net/2433/254630 |
| PMID | 32436013 |
| PQID | 2417166682 |
| PQPubID | 54039 |
| PageCount | 9 |
| ParticipantIDs | proquest_miscellaneous_2405335993 proquest_journals_2417166682 pubmed_primary_32436013 crossref_citationtrail_10_1007_s00277_020_04084_5 crossref_primary_10_1007_s00277_020_04084_5 springer_journals_10_1007_s00277_020_04084_5 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2020-07-01 |
| PublicationDateYYYYMMDD | 2020-07-01 |
| PublicationDate_xml | – month: 07 year: 2020 text: 2020-07-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Berlin/Heidelberg |
| PublicationPlace_xml | – name: Berlin/Heidelberg – name: Germany – name: Berlin |
| PublicationTitle | Annals of hematology |
| PublicationTitleAbbrev | Ann Hematol |
| PublicationTitleAlternate | Ann Hematol |
| PublicationYear | 2020 |
| Publisher | Springer Berlin Heidelberg Springer Nature B.V |
| Publisher_xml | – name: Springer Berlin Heidelberg – name: Springer Nature B.V |
| References | Stevens, Verschuuren, Pronk, van der Bij, Harmsen, The, Meijer, van den Brule, Middeldorp (CR5) 2001; 97 Crane, Powell, Kostadinov, Rocafort, Rifkin, Burger, Ambinder, Swinnen, Borowitz, Duffield (CR39) 2015; 6 Margolskee, Jobanputra, Jain, Chen, Ganapathi, Nahum, Levy, Morscio, Murty, Tousseyn, Alobeid, Mansukhani, Bhagat (CR15) 2016; 7 Trusson, Serre, Szwarc, Brunot, Garrigue, Delmas, Kanouni, Cartron, Mourad (CR21) 2016; 48 Zimmermann, Babel, Dierickx, Morschhauser, Mollee, Zaucha, Dreyling, Dührsen, Reinke, Verhoef, Subklewe, Hüttmann, Tousseyn, Bachy, Hauser, Tarella, van den Neste, Gheysens, Anagnostopoulos, Leblond, Riess, Choquet, Trappe (CR25) 2018; 102 Morscio, Dierickx, Ferreiro, Herreman, van Loo, Bittoun, Verhoef, Matthys, Cools, Wlodarska, de Wolf-Peeters, Sagaert, Tousseyn (CR11) 2013; 13 Menter, Dickenmann, Juskevicius, Steiger, Dirnhofer, Tzankov (CR12) 2017; 35 Baecklund, Backlin, Iliadou, Granath, Ekbom, Amini, Feltelius, Enblad, Sundström, Klareskog, Askling, Rosenquist (CR23) 2006; 54 Al-Mansour, Nelson, Evens (CR8) 2013; 8 Kinch, Sundström, Baecklund, Backlin, Molin, Enblad (CR35) 2019; 60 Marcelis, Tousseyn (CR37) 2019; 12 DeStefano, Desai, Shenoy, Catlett (CR16) 2018; 182 Inui, Matsuoka, Yakushijin, Okamura, Shimada, Yano, Takeuchi, Ito, Murayama, Yamamoto, Itoh, Aiba, Minami (CR31) 2015; 56 Hasserjian, Chen, Perkins, de Leval, Kinney, Barry, Said, Lim, Finn, Medeiros, Harris, O'Malley (CR3) 2009; 22 Okazaki, Honjo (CR27) 2007; 19 Xu, Zhang, Mo, Zhang, Chen, Han, Chen, Wang, Yan, Wang, Wang, Zhao, Liu, Liu, Huang (CR18) 2015; 21 Miyazaki, Fujimaki, Shirasugi, Yoshiba, Ohsaka, Miyazaki, Yamazaki, Sakai, Tamaru, Kishi, Kanamori, Higashihara, Hotta, Ishigatsubo (CR7) 2007; 82 Vakiani, Basso, Klein, Mansukhani, Narayan, Smith, Murty, Dalla-Favera, Pasqualucci, Bhagat (CR14) 2008; 26 Niitsu, Okamoto, Nakamine, Hirano (CR24) 2010; 101 Chetty, Biddolph, Kaklamanis (CR4) 1996; 28 Timms, Bell, Flavell, Murray, Rickinson, Traverse-Glehen, Berger, Delecluse (CR6) 2003; 361 Salloum, Cooper, Howe, Lacy, Tallini, Crouch, Schultz, Murren (CR30) 1996; 14 Ashrafi, Shahidi, Ebrahimi, Mortazavi (CR38) 2015; 9 Rosenberg, Klein, Ruthazer, Evens (CR10) 2016; 91 Grigg, Ritchie (CR26) 2004; 10 Evens, Choquet, Kroll-Desrosiers, Jagadeesh, Smith, Morschhauser, Leblond, Roy, Barton, Gordon, Gandhi, Dierickx, Schiff, Habermann, Trappe (CR9) 2013; 13 Balandraud, Meynard, Auger, Sovran, Mugnier, Reviron, Roudier, Roudier (CR22) 2003; 48 Baird, Van Zyl-Smit, Dilke, Scott, Rassam (CR29) 2002; 118 Montanari, Radeski, Seshan, Alobeid, Bhagat, O’Connor (CR19) 2015; 171 Bollard, Savoldo, Rooney, Heslop (CR43) 2003; 110 Bollard, Rooney, Heslop (CR44) 2012; 9 Ricciardelli, Blundell, Brewin, Thrasher, Pule, Amrolia (CR41) 2014; 124 Hoshida, Xu, Fujita, Nakamichi, Ikeda, Tomita, Nakatsuka, Tamaru, Iizuka, Takeuchi, Aozasa (CR17) 2007; 34 Lam (CR20) 2015; 6 Miyoshi, Kiyasu, Kato, Yoshida, Shimono, Yokoyama, Taniguchi, Sasaki, Kurita, Kawamoto, Kato, Imaizumi, Seto, Ohshima (CR36) 2016; 128 Barker, Doubrovina, Sauter, Jaroscak, Perales, Doubrovin, Prockop, Koehne, O'Reilly (CR42) 2010; 116 Menter, Juskevicius, Alikian, Steiger, Dirnhofer, Tzankov, Naresh (CR13) 2017; 178 Ménétrier-Caux, Ray-Coquard, Blay, Caux (CR28) 2019; 7 Mariette, Cazals-Hatem, Warszawki, Liote, Balandraud, Sibilia (CR2) 2002; 99 Burns, Crawford (CR40) 2004; 18 Dierickx, Tousseyn, Gheysens (CR1) 2015; 126 Kataoka, Miyoshi, Sakata, Dobashi, Couronné, Kogure, Sato, Nishida, Gion, Shiraishi, Tanaka, Chiba, Watatani, Kakiuchi, Shiozawa, Yoshizato, Yoshida, Makishima, Sanada, Onozawa, Teshima, Yoshiki, Ishida, Suzuki, Shimada, Tomita, Kato, Ota, Izutsu, Demachi-Okamura, Akatsuka, Miyano, Yoshino, Gaulard, Hermine, Takeuchi, Ohshima, Ogawa (CR34) 2019; 33 Trappe, Oertel, Leblond, Mollee, Sender, Reinke, Neuhaus, Lehmkuhl, Horst, Salles, Morschhauser, Jaccard, Lamy, Leithäuser, Zimmermann, Anagnostopoulos, Raphael, Riess, Choquet (CR32) 2012; 13 DeStefano, Malkovska, Rafei (CR33) 2017; 99 C Ménétrier-Caux (4084_CR28) 2019; 7 H Zimmermann (4084_CR25) 2018; 102 T Okazaki (4084_CR27) 2007; 19 N Balandraud (4084_CR22) 2003; 48 GM Crane (4084_CR39) 2015; 6 JN Barker (4084_CR42) 2010; 116 SJC Stevens (4084_CR5) 2001; 97 J Morscio (4084_CR11) 2013; 13 E Salloum (4084_CR30) 1996; 14 R Chetty (4084_CR4) 1996; 28 L-P Xu (4084_CR18) 2015; 21 F Ashrafi (4084_CR38) 2015; 9 Y Hoshida (4084_CR17) 2007; 34 CB DeStefano (4084_CR33) 2017; 99 Z Al-Mansour (4084_CR8) 2013; 8 D Dierickx (4084_CR1) 2015; 126 T Menter (4084_CR13) 2017; 178 R Trappe (4084_CR32) 2012; 13 AM Evens (4084_CR9) 2013; 13 CB DeStefano (4084_CR16) 2018; 182 E Baecklund (4084_CR23) 2006; 54 K Kataoka (4084_CR34) 2019; 33 JM Timms (4084_CR6) 2003; 361 RD Baird (4084_CR29) 2002; 118 AS Rosenberg (4084_CR10) 2016; 91 E Vakiani (4084_CR14) 2008; 26 E Margolskee (4084_CR15) 2016; 7 CM Bollard (4084_CR43) 2003; 110 Y Inui (4084_CR31) 2015; 56 L Marcelis (4084_CR37) 2019; 12 H Miyoshi (4084_CR36) 2016; 128 F Montanari (4084_CR19) 2015; 171 R Trusson (4084_CR21) 2016; 48 DM Burns (4084_CR40) 2004; 18 CM Bollard (4084_CR44) 2012; 9 X Mariette (4084_CR2) 2002; 99 RP Hasserjian (4084_CR3) 2009; 22 A Grigg (4084_CR26) 2004; 10 A Kinch (4084_CR35) 2019; 60 GY Lam (4084_CR20) 2015; 6 N Niitsu (4084_CR24) 2010; 101 I Ricciardelli (4084_CR41) 2014; 124 T Menter (4084_CR12) 2017; 35 T Miyazaki (4084_CR7) 2007; 82 |
| References_xml | – volume: 110 start-page: 139 issue: 2–3 year: 2003 end-page: 148 ident: CR43 article-title: Adoptive T-cell therapy for EBV-associated post-transplant lymphoproliferative disease publication-title: Acta Haematol doi: 10.1159/000072463 – volume: 7 start-page: 37636 issue: 25 year: 2016 end-page: 37648 ident: CR15 article-title: Genetic landscape of T- and NK-cell post-transplant lymphoproliferative disorders publication-title: Oncotarget doi: 10.18632/oncotarget.9400 – volume: 19 start-page: 813 issue: 7 year: 2007 end-page: 824 ident: CR27 article-title: PD-1 and PD-1 ligands: from discovery to clinical application publication-title: Int Immunol doi: 10.1093/intimm/dxm057 – volume: 9 start-page: 26 issue: 1 year: 2015 end-page: 32 ident: CR38 article-title: Outcome of rapamycin therapy for post-transplant-lymphoproliferative disorder after kidney transplantation: case series publication-title: Int J Hematol Stem Cell Res – volume: 54 start-page: 3774 issue: 12 year: 2006 end-page: 3781 ident: CR23 article-title: Characteristics of diffuse large B cell lymphomas in rheumatoid arthritis publication-title: Arthritis Rheum doi: 10.1002/art.22277 – volume: 12 start-page: 3 issue: 1 year: 2019 end-page: 16 ident: CR37 article-title: The tumor microenvironment in post-transplant lymphoproliferative disorders publication-title: Cancer Microenviron doi: 10.1007/s12307-018-00219-5 – volume: 34 start-page: 322 issue: 2 year: 2007 end-page: 331 ident: CR17 article-title: Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication publication-title: J Rheumatol – volume: 60 start-page: 376 issue: 2 year: 2019 end-page: 384 ident: CR35 article-title: Expression of PD-1, PD-L1, and PD-L2 in posttransplant lymphoproliferative disorder after solid organ transplantation publication-title: Leuk Lymphoma doi: 10.1080/10428194.2018.1480767 – volume: 128 start-page: 1374 issue: 10 year: 2016 end-page: 1381 ident: CR36 article-title: PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia/lymphoma publication-title: Blood doi: 10.1182/blood-2016-02-698936 – volume: 118 start-page: 567 issue: 2 year: 2002 end-page: 568 ident: CR29 article-title: Spontaneous remission of low-grade B-cell non-Hodgkin’s lymphoma following withdrawal of methotrexate in a patient with rheumatoid arthritis: case report and review of the literature publication-title: Br J Haematol doi: 10.1046/j.1365-2141.2002.03619.x – volume: 56 start-page: 3045 issue: 11 year: 2015 end-page: 3051 ident: CR31 article-title: Methotrexate-associated lymphoproliferative disorders: management by watchful waiting and observation of early lymphocyte recovery after methotrexate withdrawal publication-title: Leuk Lymphoma doi: 10.3109/10428194.2015.1022769 – volume: 9 start-page: 510 issue: 9 year: 2012 end-page: 519 ident: CR44 article-title: T-cell therapy in the treatment of post-transplant lymphoproliferative disease publication-title: Nat Rev Clin Oncol doi: 10.1038/nrclinonc.2012.111 – volume: 124 start-page: 2514 issue: 16 year: 2014 end-page: 2523 ident: CR41 article-title: Towards gene therapy for EBV-associated posttransplant lymphoma with genetically modi fied EBV-specific cytotoxic T cells publication-title: Blood doi: 10.1182/blood-2014-01-553362 – volume: 82 start-page: 1106 issue: 12 year: 2007 end-page: 1109 ident: CR7 article-title: Remission of lymphoma after withdrawal of methotrexate in rheumatoid arthritis: relationship with type of latent Epstein-Barr virus infection publication-title: Am J Hematol doi: 10.1002/ajh.21003 – volume: 116 start-page: 5045 issue: 23 year: 2010 end-page: 5049 ident: CR42 article-title: Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes publication-title: Blood doi: 10.1182/blood-2010-04-281873 – volume: 8 start-page: 173 issue: 3 year: 2013 end-page: 183 ident: CR8 article-title: Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies publication-title: Curr Hematol Malig Rep doi: 10.1007/s11899-013-0162-5 – volume: 13 start-page: 1305 issue: 5 year: 2013 end-page: 1316 ident: CR11 article-title: Gene expression profiling reveals clear differences between EBV-positive and EBV-negative posttransplant lymphoproliferative disorders publication-title: Am J Transplant doi: 10.1111/ajt.12196 – volume: 7 start-page: 85 issue: 1 year: 2019 ident: CR28 article-title: Lymphopenia in cancer patients and its effects on response to immunotherapy: an opportunity for combination with cytokines? publication-title: J Immunother Cancer doi: 10.1186/s40425-019-0549-5 – volume: 26 start-page: 199 issue: 4 year: 2008 end-page: 211 ident: CR14 article-title: Genetic and phenotypic analysis of B-cell post-transplant lymphoproliferative disorders provides insights into disease biology publication-title: Hematol Oncol doi: 10.1002/hon.859 – volume: 171 start-page: 491 issue: 4 year: 2015 end-page: 500 ident: CR19 article-title: Recursive partitioning analysis of prognostic factors in post-transplant lymphoproliferative disorders (PTLD): a 120 case single institution series publication-title: Br J Haematol doi: 10.1111/bjh.13621 – volume: 182 start-page: 330 issue: 3 year: 2018 end-page: 343 ident: CR16 article-title: Management of post-transplant lymphoproliferative disorders publication-title: Br J Haematol doi: 10.1111/bjh.15263 – volume: 99 start-page: 3909 issue: 11 year: 2002 end-page: 3915 ident: CR2 article-title: Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France publication-title: Blood doi: 10.1182/blood.V99.11.3909 – volume: 13 start-page: 196 issue: 2 year: 2012 end-page: 206 ident: CR32 article-title: Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(11)70300-X – volume: 21 start-page: 2185 issue: 12 year: 2015 end-page: 2191 ident: CR18 article-title: Epstein-Barr virus–related post-transplantation lymphoproliferative disorder after unmanipulated human leukocyte antigen haploidentical hematopoietic stem cell transplantation: incidence, risk factors, treatment, and clinical outcomes publication-title: Biol Blood Marrow Transplant doi: 10.1016/j.bbmt.2015.07.035 – volume: 14 start-page: 1943 issue: 6 year: 1996 end-page: 1949 ident: CR30 article-title: Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases publication-title: J Clin Oncol doi: 10.1200/JCO.1996.14.6.1943 – volume: 126 start-page: 2274 issue: 20 year: 2015 end-page: 2283 ident: CR1 article-title: How i treat posttransplant lymphoproliferative disorders publication-title: Blood doi: 10.1182/blood-2015-05-615872 – volume: 18 start-page: 193 issue: 3 year: 2004 end-page: 209 ident: CR40 article-title: Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease publication-title: Blood Rev doi: 10.1016/j.blre.2003.12.002 – volume: 48 start-page: 1927 issue: 6 year: 2016 end-page: 1933 ident: CR21 article-title: Treatment response and outcomes in post-transplantation lymphoproliferative disease vs lymphoma in Immunocompetent patients publication-title: Transplant Proc doi: 10.1016/j.transproceed.2016.03.045 – volume: 13 start-page: 1512 issue: 6 year: 2013 end-page: 1522 ident: CR9 article-title: Primary CNS posttransplant lymphoproliferative disease (PTLD): an international report of 84 cases in the modern era publication-title: Am J Transplant doi: 10.1111/ajt.12211 – volume: 10 start-page: 579 issue: 9 year: 2004 end-page: 590 ident: CR26 article-title: Graft-versus-lymphoma effects: clinical review, policy proposals, and immunobiology publication-title: Biol Blood Marrow Transplant doi: 10.1016/j.bbmt.2004.05.008 – volume: 28 start-page: 257 issue: 3 year: 1996 end-page: 260 ident: CR4 article-title: EBV latent membrane protein (LMP-1) and bcl-2 protein expression in Reed-Sternberg-like cells in post-transplant lymphoproliferative disorders publication-title: Histopathology doi: 10.1046/j.1365-2559.1996.d01-425.x – volume: 101 start-page: 1309 issue: 5 year: 2010 end-page: 1313 ident: CR24 article-title: Clinicopathologic correlations of diffuse large B-cell lymphoma in rheumatoid arthritis patients treated with methotrexate publication-title: Cancer Sci doi: 10.1111/j.1349-7006.2010.01517.x – volume: 22 start-page: 1532 issue: 12 year: 2009 end-page: 1540 ident: CR3 article-title: Immunomodulator agent-related lymphoproliferative disorders publication-title: Mod Pathol doi: 10.1038/modpathol.2009.131 – volume: 48 start-page: 1223 issue: 5 year: 2003 end-page: 1228 ident: CR22 article-title: Epstein-Barr virus load in the peripheral blood of patients with rheumatoid arthritis: accurate quantification using real-time polymerase chain reaction publication-title: Arthritis Rheum doi: 10.1002/art.10933 – volume: 102 start-page: 1914 issue: 11 year: 2018 end-page: 1923 ident: CR25 article-title: Immunosuppression is associated with clinical features and relapse risk of B cell posttransplant lymphoproliferative disorder publication-title: Transplantation doi: 10.1097/TP.0000000000002269 – volume: 6 start-page: 33849 issue: 32 year: 2015 end-page: 33866 ident: CR39 article-title: Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage publication-title: Oncotarget doi: 10.18632/oncotarget.5292 – volume: 91 start-page: 560 issue: 6 year: 2016 end-page: 565 ident: CR10 article-title: Hodgkin lymphoma post-transplant lymphoproliferative disorder: a comparative analysis of clinical characteristics, prognosis, and survival publication-title: Am J Hematol doi: 10.1002/ajh.24346 – volume: 6 start-page: 181 issue: 4 year: 2015 ident: CR20 article-title: Lymphoproliferative disorders in inflammatory bowel disease patients on immunosuppression: lessons from other inflammatory disorders publication-title: World J Gastrointest Pathophysiol doi: 10.4291/wjgp.v6.i4.181 – volume: 97 start-page: 1165 issue: 5 year: 2001 end-page: 1171 ident: CR5 article-title: Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients publication-title: Blood doi: 10.1182/blood.V97.5.1165 – volume: 99 start-page: 283 issue: 3 year: 2017 end-page: 285 ident: CR33 article-title: DA-EPOCH-R for post-transplant lymphoproliferative disorders publication-title: Eur J Haematol doi: 10.1111/ejh.12904 – volume: 35 start-page: 187 issue: 2 year: 2017 end-page: 197 ident: CR12 article-title: Comprehensive phenotypic characterization of PTLD reveals potential reliance on EBV or NF-κB signalling instead of B-cell receptor signalling publication-title: Hematol Oncol doi: 10.1002/hon.2280 – volume: 361 start-page: 217 issue: 9353 year: 2003 end-page: 223 ident: CR6 article-title: Target cells of Epstein-Barr-virus (EBV)-positive post-transplant lymphoproliferative disease: similarities to EBV-positive Hodgkin’s lymphoma publication-title: Lancet doi: 10.1016/S0140-6736(03)12271-4 – volume: 178 start-page: 48 issue: 1 year: 2017 end-page: 56 ident: CR13 article-title: Mutational landscape of B-cell post-transplant lymphoproliferative disorders publication-title: Br J Haematol doi: 10.1111/bjh.14633 – volume: 33 start-page: 1687 issue: 7 year: 2019 end-page: 1699 ident: CR34 article-title: Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas publication-title: Leukemia doi: 10.1038/s41375-019-0380-5 – volume: 91 start-page: 560 issue: 6 year: 2016 ident: 4084_CR10 publication-title: Am J Hematol doi: 10.1002/ajh.24346 – volume: 102 start-page: 1914 issue: 11 year: 2018 ident: 4084_CR25 publication-title: Transplantation doi: 10.1097/TP.0000000000002269 – volume: 9 start-page: 510 issue: 9 year: 2012 ident: 4084_CR44 publication-title: Nat Rev Clin Oncol doi: 10.1038/nrclinonc.2012.111 – volume: 10 start-page: 579 issue: 9 year: 2004 ident: 4084_CR26 publication-title: Biol Blood Marrow Transplant doi: 10.1016/j.bbmt.2004.05.008 – volume: 118 start-page: 567 issue: 2 year: 2002 ident: 4084_CR29 publication-title: Br J Haematol doi: 10.1046/j.1365-2141.2002.03619.x – volume: 60 start-page: 376 issue: 2 year: 2019 ident: 4084_CR35 publication-title: Leuk Lymphoma doi: 10.1080/10428194.2018.1480767 – volume: 110 start-page: 139 issue: 2–3 year: 2003 ident: 4084_CR43 publication-title: Acta Haematol doi: 10.1159/000072463 – volume: 56 start-page: 3045 issue: 11 year: 2015 ident: 4084_CR31 publication-title: Leuk Lymphoma doi: 10.3109/10428194.2015.1022769 – volume: 19 start-page: 813 issue: 7 year: 2007 ident: 4084_CR27 publication-title: Int Immunol doi: 10.1093/intimm/dxm057 – volume: 54 start-page: 3774 issue: 12 year: 2006 ident: 4084_CR23 publication-title: Arthritis Rheum doi: 10.1002/art.22277 – volume: 178 start-page: 48 issue: 1 year: 2017 ident: 4084_CR13 publication-title: Br J Haematol doi: 10.1111/bjh.14633 – volume: 18 start-page: 193 issue: 3 year: 2004 ident: 4084_CR40 publication-title: Blood Rev doi: 10.1016/j.blre.2003.12.002 – volume: 116 start-page: 5045 issue: 23 year: 2010 ident: 4084_CR42 publication-title: Blood doi: 10.1182/blood-2010-04-281873 – volume: 97 start-page: 1165 issue: 5 year: 2001 ident: 4084_CR5 publication-title: Blood doi: 10.1182/blood.V97.5.1165 – volume: 34 start-page: 322 issue: 2 year: 2007 ident: 4084_CR17 publication-title: J Rheumatol – volume: 48 start-page: 1927 issue: 6 year: 2016 ident: 4084_CR21 publication-title: Transplant Proc doi: 10.1016/j.transproceed.2016.03.045 – volume: 33 start-page: 1687 issue: 7 year: 2019 ident: 4084_CR34 publication-title: Leukemia doi: 10.1038/s41375-019-0380-5 – volume: 13 start-page: 196 issue: 2 year: 2012 ident: 4084_CR32 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(11)70300-X – volume: 124 start-page: 2514 issue: 16 year: 2014 ident: 4084_CR41 publication-title: Blood doi: 10.1182/blood-2014-01-553362 – volume: 171 start-page: 491 issue: 4 year: 2015 ident: 4084_CR19 publication-title: Br J Haematol doi: 10.1111/bjh.13621 – volume: 12 start-page: 3 issue: 1 year: 2019 ident: 4084_CR37 publication-title: Cancer Microenviron doi: 10.1007/s12307-018-00219-5 – volume: 13 start-page: 1512 issue: 6 year: 2013 ident: 4084_CR9 publication-title: Am J Transplant doi: 10.1111/ajt.12211 – volume: 7 start-page: 37636 issue: 25 year: 2016 ident: 4084_CR15 publication-title: Oncotarget doi: 10.18632/oncotarget.9400 – volume: 22 start-page: 1532 issue: 12 year: 2009 ident: 4084_CR3 publication-title: Mod Pathol doi: 10.1038/modpathol.2009.131 – volume: 6 start-page: 181 issue: 4 year: 2015 ident: 4084_CR20 publication-title: World J Gastrointest Pathophysiol doi: 10.4291/wjgp.v6.i4.181 – volume: 82 start-page: 1106 issue: 12 year: 2007 ident: 4084_CR7 publication-title: Am J Hematol doi: 10.1002/ajh.21003 – volume: 35 start-page: 187 issue: 2 year: 2017 ident: 4084_CR12 publication-title: Hematol Oncol doi: 10.1002/hon.2280 – volume: 128 start-page: 1374 issue: 10 year: 2016 ident: 4084_CR36 publication-title: Blood doi: 10.1182/blood-2016-02-698936 – volume: 7 start-page: 85 issue: 1 year: 2019 ident: 4084_CR28 publication-title: J Immunother Cancer doi: 10.1186/s40425-019-0549-5 – volume: 182 start-page: 330 issue: 3 year: 2018 ident: 4084_CR16 publication-title: Br J Haematol doi: 10.1111/bjh.15263 – volume: 14 start-page: 1943 issue: 6 year: 1996 ident: 4084_CR30 publication-title: J Clin Oncol doi: 10.1200/JCO.1996.14.6.1943 – volume: 48 start-page: 1223 issue: 5 year: 2003 ident: 4084_CR22 publication-title: Arthritis Rheum doi: 10.1002/art.10933 – volume: 8 start-page: 173 issue: 3 year: 2013 ident: 4084_CR8 publication-title: Curr Hematol Malig Rep doi: 10.1007/s11899-013-0162-5 – volume: 9 start-page: 26 issue: 1 year: 2015 ident: 4084_CR38 publication-title: Int J Hematol Stem Cell Res – volume: 28 start-page: 257 issue: 3 year: 1996 ident: 4084_CR4 publication-title: Histopathology doi: 10.1046/j.1365-2559.1996.d01-425.x – volume: 13 start-page: 1305 issue: 5 year: 2013 ident: 4084_CR11 publication-title: Am J Transplant doi: 10.1111/ajt.12196 – volume: 361 start-page: 217 issue: 9353 year: 2003 ident: 4084_CR6 publication-title: Lancet doi: 10.1016/S0140-6736(03)12271-4 – volume: 21 start-page: 2185 issue: 12 year: 2015 ident: 4084_CR18 publication-title: Biol Blood Marrow Transplant doi: 10.1016/j.bbmt.2015.07.035 – volume: 126 start-page: 2274 issue: 20 year: 2015 ident: 4084_CR1 publication-title: Blood doi: 10.1182/blood-2015-05-615872 – volume: 26 start-page: 199 issue: 4 year: 2008 ident: 4084_CR14 publication-title: Hematol Oncol doi: 10.1002/hon.859 – volume: 99 start-page: 3909 issue: 11 year: 2002 ident: 4084_CR2 publication-title: Blood doi: 10.1182/blood.V99.11.3909 – volume: 101 start-page: 1309 issue: 5 year: 2010 ident: 4084_CR24 publication-title: Cancer Sci doi: 10.1111/j.1349-7006.2010.01517.x – volume: 6 start-page: 33849 issue: 32 year: 2015 ident: 4084_CR39 publication-title: Oncotarget doi: 10.18632/oncotarget.5292 – volume: 99 start-page: 283 issue: 3 year: 2017 ident: 4084_CR33 publication-title: Eur J Haematol doi: 10.1111/ejh.12904 |
| SSID | ssj0012842 |
| Score | 2.2766626 |
| Snippet | The number of patients who are administered immunosuppressive agents has been increasing. Accordingly, more patients face higher risks for developing... |
| SourceID | proquest pubmed crossref springer |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1565 |
| SubjectTerms | Hematology Lymphatic diseases Lymphoma Medical diagnosis Medicine Medicine & Public Health Oncology Original Article Tumors |
| SummonAdditionalLinks | – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Na9wwEB3SDYReSj-SdJO0qNBbI2LLnlg-lNKWhFCapZQGcjOyJMNCWG9j76H_vjOy7BBC4qtkWfiNpJGe5g3ARzIBzzpiMmlK2qDYJJGmSFAarSzmmdUOOXb4cnF6cZX_uMbrLViMsTB8rXKcE8NE7VrLZ-QntNIUTHFp9WX9V3LWKGZXxxQaJqZWcJ-DxNgz2FasjDWD7W9ni1-_J16BJuPAK5RZKZGeGEYTgumSQGfydooMW-cS7y9VD_zPB9xpWJLOX8KL6EuKrwP4r2DLr17DzmVky9_A5uc_worzYy2NML1ww7W6ZSfWt1yp70S3oamCjE20jYgSq53gs1mx5MCR1nlWmODwTGkikN6Jm6FdTvjT-EE6XLgo49ntwtX52Z_vFzKmWZA219hL8hFKk2ZNavPcadtYo01eGG-VTVLrPHrPsnG10i715F96f2qakulUVFiTi7MHs1W78m9B1FnhHCpTYuLzGm2dlrbRViM2KitKO4d0_KOVjRrknArjpprUkwMKFaFQBRQqnMOn6Z31oMDxZO2jEagqjsauurOdOXyYimkcMTliVr7dcB2OSkZy1-awPwA8fY6czow2rlRyPCJ-1_jjfTl4ui-H8FwFa-O7v0cw6283_h15OH39PprtfwOB-DU priority: 102 providerName: ProQuest |
| Title | Lymphopenia at diagnosis predicts survival of patients with immunodeficiency-associated lymphoproliferative disorders |
| URI | https://link.springer.com/article/10.1007/s00277-020-04084-5 https://www.ncbi.nlm.nih.gov/pubmed/32436013 https://www.proquest.com/docview/2417166682 https://www.proquest.com/docview/2405335993 |
| Volume | 99 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVLSH databaseName: SpringerLink Journals customDbUrl: mediaType: online eissn: 1432-0584 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0012842 issn: 0939-5555 databaseCode: AFBBN dateStart: 19970101 isFulltext: true providerName: Library Specific Holdings – providerCode: PRVAVX databaseName: HAS SpringerNature Open Access 2022 customDbUrl: eissn: 1432-0584 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0012842 issn: 0939-5555 databaseCode: AAJSJ dateStart: 19970101 isFulltext: true titleUrlDefault: https://www.springernature.com providerName: Springer Nature – providerCode: PRVAVX databaseName: Springer Nature OA Free Journals customDbUrl: eissn: 1432-0584 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0012842 issn: 0939-5555 databaseCode: C6C dateStart: 19550301 isFulltext: true titleUrlDefault: http://www.springeropen.com/ providerName: Springer Nature – providerCode: PRVAVX databaseName: SpringerLINK - Czech Republic Consortium customDbUrl: eissn: 1432-0584 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0012842 issn: 0939-5555 databaseCode: AGYKE dateStart: 19970101 isFulltext: true titleUrlDefault: http://link.springer.com providerName: Springer Nature – providerCode: PRVAVX databaseName: SpringerLink Journals (ICM) customDbUrl: eissn: 1432-0584 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0012842 issn: 0939-5555 databaseCode: U2A dateStart: 19970101 isFulltext: true titleUrlDefault: http://www.springerlink.com/journals/ providerName: Springer Nature |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3Pa9swFH6sLYxdRrtfzdoGDXbbBLbsF8vHJCQr2xrGWCA7GVmSIVCSUjuH_fd7z5Y9RrfBfNFBsmz8Pcuf_Ol9AnhLIeDZR0xGVU4TFBtF0mQRSqOVxTSx2iHnDt-sJtfr9OMGNyEprO5Xu_eSZDtSD8luUSs38nSHAk-nEo_gBNnOi6J4raaDdkADbqsd5EkukY6QKvPnPn7_HD3gmA_00fazszyFp4EvimkH8Bk88rtn8PgmKOLP4fD5B-HBe2BtjTCNcN3SuW0t7u65UVOL-kDDAQWU2Fci2KjWgv-_ii0nh-ydZxcJTsGUJoDlnbjt-uVNfSrf2YMLF6w66xewXi6-za9l2EpB2lRjI4kH5CZOqtimqdO2skabNDPeKhvF1nn0nq3hSqVd7IlDej8xVc6SKSosica8hOPdfufPQZRJ5hwqk2Pk0xJtGee20lYjVirJcjuCuH-ihQ0-47zdxW0xOCS3KBSEQtGiUOAI3g3n3HUuG_9sfdkDVYQ3ri6IiWQsgWo1gjdDNb0rLICYnd8fuA1nHiNRshG86gAeLkfEMqHJKdW87xH_1fnf7-X1_zW_gCeqjT5e73sJx839wV8Rq2nKMRxlm2wMJ9PlbLbi8sP3TwsqZ4vVl69UO5_Mx22g_wSjg_T5 |
| linkProvider | Springer Nature |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Nb9QwEB2VVgIuqHwvFDASnMAicezGOVRVgVZburtCqJV6Sx3bkVaqNkuTFeqf47d1JnFSoYremqsdJ_KMPTN-njcAH1AFPPGI8ajMMECxUcRNGilutLBKJlY7RbnD09n2-ET-OFWna_C3z4Wha5X9nthu1K6ydEb-BS1NShCXFrvL35yqRhG62pfQMKG0gttpKcZCYseRv_yDIVy9c_gd5f1RiIP9429jHqoMcCu1ajiayMzESRlbKZ22pTXayNR4K2wUW-eV98SaVgjtYo_ulffbpswITVRCFWjhcdx7sCETmWHwt_F1f_bz14Bj4Obf4hhZknGFT0jbaZP3ohY-pfANF5KWXP1rGm_4uzew2tYEHmzCo-C7sr1O2R7Dml88gfvTgM4_hdXkEnWD6nHNDTMNc901vnnNlhfUqalZvcKtCZWbVSULlK41o7NgNqdElcp5YrSgdFBuguJ4x867canAUOk7qnLmAm1o_QxO7mTCn8P6olr4l8CKJHVOCZOpyMtC2SLObKmtVqoUSZrZEcT9jOY2cJ5T6Y3zfGBrbqWQoxTyVgq5GsGn4Z1lx_hxa--tXlB5WP11fq2rI3g_NOO6JTDGLHy1oj6UBa3QPRzBi07Aw-fQyU0wUMaWz73Erwf__7-8uv1f3sGD8fF0kk8OZ0ev4aFoNY_uHW_BenOx8m_Qu2qKt0GFGZzd9aq5AiKzNdA |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3da9RAEB9qheKLqFV7WnWF-lSXJptss_sgItajtR_40MK9xc1-wEG5nE0O6b_mX-dMskmRYt96r9nshcxvdmYyM78B2EEIeOIR40nQGKDYJOGmSCQ3SliZZ1Y5Sb3Dp2f7hxf595mcrcGfoReGyiqHM7E7qF1t6Rv5HlqaglJcSuyFWBbx42D6efmL0wQpyrQO4zR6iBz7698YvjWfjg5Q1h-EmH47_3rI44QBbnMlW47mUZs0C6nNc6dssEaZvDDeCpuk1nnpPTGmVUK51KNr5f2-CZoyiVLICq077vsAHhZZpqmcsJiNwR4d-10GQ2eaS_zFhp2ubS_pEqcUuKEKqZzLf43iLU_3Vpa2M37TJ_A4eq3sSw-zp7DmF89g4zTm5TdhdXKNqKBJXHPDTMtcX8A3b9jyiha1DWtWeCghrFkdWCRzbRh9BWZzalGpnScuC2oE5SZCxjt22e9Lo4WC70nKmYuEoc1zuLiX1_0C1hf1wm8Bq7LCOSmMlonPK2mrVNugrJIyiKzQdgLp8EZLG9nOaejGZTnyNHdSKFEKZSeFUk5gd7xn2XN93Ll6exBUGfW-KW9QOoH342XUWErDmIWvV7SG-p8lOoYTeNkLePw7dG8zDJHxysdB4jeb__9ZXt39LO9gA3WlPDk6O34Nj0QHPCo43ob19mrl36Bb1VZvO_wy-HnfCvMXpS4zag |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Lymphopenia+at+diagnosis+predicts+survival+of+patients+with+immunodeficiency-associated+lymphoproliferative+disorders&rft.jtitle=Annals+of+hematology&rft.au=Watanabe%2C+Mizuki&rft.au=Kanda%2C+Junya&rft.au=Hishizawa%2C+Masakatsu&rft.au=Nishikori%2C+Momoko&rft.date=2020-07-01&rft.eissn=1432-0584&rft_id=info:doi/10.1007%2Fs00277-020-04084-5&rft_id=info%3Apmid%2F32436013&rft.externalDocID=32436013 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0939-5555&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0939-5555&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0939-5555&client=summon |